Abstract:Atherosclerosis is a multi-factorial inflammatory disease with accumulation of lipids and recruitment of leukocytes into the subendothelial space. Due to the consistent inflammation in vessels, a subset of atherosclerotic plaques is even prone to physical disruption or producing thrombosis that triggers acute coronary syndromes (ACS). Cyclooxygenase (COX) and the downstream diverse prostanoids are involved in numerous physiological activities and inflammatory processes. Remarkably, prostanoids are a group of bioactive lipid mediators, and play a series of complicated and even contradictory roles during the progression of atherogenesis. Some, mainly prostacyclin (PGI2) have cardioprotective effects to inhibit the aggravation of atherosclerosis, however, others including prostaglandin E2 (PGE2) and thromboxane A2 (TXA2), increase the risk of cardiovascular thromboembolic events. Therefore, the controversial effects bring about a debate on the use of cyclooxygenase-2 (COX-2) specific and non-specific inhibitors in the prevention from cardiovascular diseases. In addition to reverse cholesterol transport (RCT), high-density lipoprotein (HDL) exerts several beneficial effects on endothelial protection. Moreover, HDL could also regulate the expression of COX-2 and the production of PGI2 in endothelial cells. While as a diverse complex of heterogeneous particle composed of various apolipoproteins, enzymes and lipids, the individual components of HDL, such as apolipoprotein A-I (apoA-I) and sphingosine-1-phosphate (S1P), have distinct effects on COX-2 expression and PGI2 production in endothelial cells. In the present review, we summarize the roles of COX-2 as well as PGI2 in atherosclerosis and atherothrombosis, the controversial vascular effects on prostanoid inhibition by COX-2 inhibitors, and the effects of HDL on the endothelial protection by the upregulation of COX-2 and the release of PGI2 during the progression of atherosclerosis.

Prostanoids in health and disease

Prostaglandins and Inflammation

Physiology and pathophysiology of prostanoid receptors

Prostanoids receptors signaling in different diseases/cancers progression.

Prostanoid biosynthesis and mechanisms of action

Eicosanoids in inflammation in the blood and the vessel

Lipid Mediators in Health and Disease: Enzymes and Receptors as Therapeutic Targets for the Regulation of Immunity and Inflammation

Prostanoids and inflammation: a new concept arising from receptor knockout mice

Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis

An Overview of Arachidonic Acid Metabolic Pathway and Recent Updates on a Few Heterocyclic Derivatives showing COX-2 Inhibition

Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.

Prostanoids in Cardiac and Vascular Remodeling

Regulation of T Helper Cell Subsets by Cyclooxygenases and Their Metabolites.

Prostanoids in Asthma and COPD: Actions, Dysregulation, and Therapeutic Opportunities

Old and new generation lipid mediators in acute inflammation and resolution

Interplay Between Oxidative Stress, Cyclooxygenases, and Prostanoids in Cardiovascular Diseases

Exploring the roles of prostanoids, leukotriens, and dietary fatty acids in cutaneous inflammatory diseases: Insights from pharmacological and genetic approaches

Cyclooxygenases: From Prostaglandin Synthesis to Innovative Therapies for Inflammation

Prostaglandin biosynthesis can be triggered by lipid peroxides

The Eicosanoids, Redox-Regulated Lipid Mediators in Immunometabolic Disorders

Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors